The France-based ANSR-106 study [14], which used a 2-month on/2-month off treatment strategy, did not result in clinical endpoint differences between arms (CD4+ T cell count >300 cells/μl), but the interrupting arm had higher frequency of lymphadenitis and candidiasis. This evidence concerns the gene CD4 and Candidiasis, Invasive.